Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update

SA Khan, BR Davidson, RD Goldin, N Heaton, J Karani… - Gut, 2012 - gut.bmj.com
The British Society of Gastroenterology guidelines on the management of
cholangiocarcinoma were originally published in 2002. This is the first update since then …

Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal …

B Nordlinger, E Van Cutsem, P Rougier… - European journal of …, 2007 - Elsevier
Liver resection offers the only chance of cure for patients with advanced colorectal cancer
(CRC). Typically, the 5-year survival rates following liver resection range from 25% to 40 …

[HTML][HTML] Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis

L Sun, L Zhang, J Yu, Y Zhang, X Pang, C Ma… - Scientific reports, 2020 - nature.com
Abstract Anti-PD-1/PD-L1 inhibitors provide a survival advantage over conventional
therapies for treatment of advanced or metastatic cancer. However, the factors determining …

[HTML][HTML] Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

J Valle, H Wasan, DH Palmer… - … England Journal of …, 2010 - Mass Medical Soc
Background There is no established standard chemotherapy for patients with locally
advanced or metastatic biliary tract cancer. We initially conducted a randomized, phase 2 …

[HTML][HTML] Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre …

JP Neoptolemos, DH Palmer, P Ghaneh, EE Psarelli… - The Lancet, 2017 - thelancet.com
Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in …

[HTML][HTML] Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled …

A Lamarca, DH Palmer, HS Wasan, PJ Ross… - The Lancet …, 2021 - thelancet.com
Background Advanced biliary tract cancer has a poor prognosis. Cisplatin and gemcitabine
is the standard first-line chemotherapy regimen, but no robust evidence is available for …

[HTML][HTML] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

S Kopetz, A Grothey, R Yaeger… - … England Journal of …, 2019 - Mass Medical Soc
Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial …

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

JN Primrose, RP Fox, DH Palmer, HZ Malik… - The Lancet …, 2019 - thelancet.com
Background Despite improvements in multidisciplinary management, patients with biliary
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection …

Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document

SA Khan, BR Davidson, R Goldin, SP Pereira… - Gut, 2002 - gut.bmj.com
2.0 BACKGROUND Mortality rates from intrahepatic cholangiocarcinoma have risen steeply
and steadily over the past 30 years and since the mid 1990s more deaths have been coded …

[HTML][HTML] Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and …

J Tabernero, A Grothey, E Van Cutsem… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with …